Table 1.
Clinical Characteristics of 7 Cases of GBS After CMV
| First Author (Ref. #) | Age, yrs/Sex | CMV Status (D/R) | Reason for Transplant | Time Until GBS | Maintenance Immunotherapy | IVIG | TPE | Max/Final Grade∗ |
|---|---|---|---|---|---|---|---|---|
| Visser et al. (6) | 62/M | +/+ | NS | 4.5 months | Cyclosporine, azathioprine, and steroids | Yes | Yes | G4/G1 |
| Visser et al. (6) | 61/M | +/− | Rheumatic | 4 months | Cyclosporine, azathioprine, and steroids | Yes | Yes | G4/G2 |
| Baldwin et al. (7) | 62/M | +/− | DCM | 5 days | Cyclosporine and steroids | Yes | Yes | G5/G2 |
| El-Sabrout et al. (8) | 44/M | NS | NS | 14 yrs | Cyclosporine, mycophenolate mofetil, and steroids | No | Yes | G4/G1 |
| Hodowanec et al. (9) | 40/M | +/− | ICM | 7 months | Cyclosporine | No | Yes | G5/G1 |
| Steger et al. (10) | 50/M | +/− | NICM | 2 yrs | NS | Yes | Yes | G5/G3 |
| Present study | 56/M | −/− | ICM | 21 months | Mycophenolate, mofetil, and tacrolimus | Yes | No | G2/G1 |
The clinical characteristics of all 7 reported cases of GBS after CMV in patients with heart transplants are summarized.
CMV = cytomegalovirus; D = donor; DCM = dilated cardiomyopathy; GBS = Guillain-Barré Syndrome; ICM = ischemic cardiomyopathy; IVIG = intravenous immunoglobulin; NICM = nonischemic cardiomyopathy; NS = not specified; R = recipient; TPE = total plasma exchange.
∗
Graded using the GBS syndrome disability (12).